Lymphoma & CLL Subtypes

Outpatient administration of liso-cel: Preliminary results from the OUTREACH study

Due to concerns regarding adverse events (AEs), chimeric antigen receptor (CAR) T-cell therapies are predominantly...

Real-world outcomes in Germany with standard-of-care axi-cel and tisa-cel for large B-cell lymphoma

Following promising results in clinical trials, the CD19-targeted chimeric antigen receptor (CAR)...

Duvelisib receives a positive opinion from the EMA CHMP for the treatment of R/R CLL and refractory FL

On March 25, 2021, it was announced that duvelisib received a positive opinion from the European...

Japanese approval of lisocabtagene maraleucel for the treatment of R/R LBCL

On March 25, 2021, it was announced that the Japanese Ministry of Health, Labour, and Welfare approved the use of...

FDA biologics license application of ublituximab plus umbralisib for the treatment of CLL

On March 29, 2021, it was announced that a biologics license application (BLA) was submitted to the U.S. Food...

A four-factor prognostic model predicts outcome in patients with CLL treated with ibrutinib

Ibrutinib is a Bruton’s tyrosine kinase inhibitor with clinical efficacy for patients with...

EC approval of pembrolizumab for adult and pediatric patients with R/R cHL

On March 18, 2021, it was announced that the European Commission (EC) approved pembrolizumab, an anti-PD-1 monoclonal...

Can CD30 CAR T-cell consolidation improve outcomes after ASCT for patients with CD30+ lymphomas?

During the 2021 TCT Meetings Digital Experience, the Lymphoma Hub spoke to Marcie Riches, UNC-Chapel...